Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant forms of cancer. Lack of effective treatment options and drug resistance contributes to the low survival among PDAC patients. In this study, we investigated the metabolic alterations in pancreatic cancer cells that do not respond t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Neha, Bhushan, Alok, He, Jun, Kaushal, Gagan, Bhardwaj, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507640/
https://www.ncbi.nlm.nih.gov/pubmed/32974013
http://dx.doi.org/10.1186/s40170-020-00226-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507640/
https://www.ncbi.nlm.nih.gov/pubmed/32974013
http://dx.doi.org/10.1186/s40170-020-00226-5

Ejemplares similares